首页> 外文期刊>Progress in Neuro-Psychopharmacology & Biological Psychiatry: An International Research, Review and News Journal >Effects of olanzapine on brain-derived neurotrophic factor gene promoter activity in SH-SY5Y neuroblastoma cells.
【24h】

Effects of olanzapine on brain-derived neurotrophic factor gene promoter activity in SH-SY5Y neuroblastoma cells.

机译:奥氮平对SH-SY5Y神经母细胞瘤细胞脑源性神经营养因子基因启动子活性的影响。

获取原文
获取原文并翻译 | 示例
           

摘要

PURPOSE: Atypical antipsychotics have neuroprotective effects, which may be one of the mechanisms for their success in the treatment of schizophrenia. Growing evidence suggest that brain-derived neurotrophic factor (BDNF) is abnormally regulated in patients with schizophrenia, and its expression can be up-regulated by atypical antipsychotics. Atypical antipsychotic drugs may positively regulate transcription of the BDNF gene, but the molecular mechanism of atypical antipsychotic drug action on BDNF gene activity has not been investigated. The aim of the present study was to explore the possible involvement of some intracellular signaling pathways in olanzapine action on BDNF promoter activity. METHODS: We examined the effects of olanzapine on BDNF gene promoter activity in SH-SY5Y cells transfected with a rat BDNF promoter fragment (-108 to +340) linked to the luciferase reporter gene. The changes in glycogen synthase kinase-3beta (GSK-3beta) and cAMP response element (CRE) binding protein (CREB) phosphorylation were measured by Western blot analysis. RESULTS: Olanzapine treatment (10-100 microM) increased basal BDNF gene promoter activity in a dose-dependent manner and increased protein levels at high dose, and inhibitors of protein kinase A (PKA), H-89 (10 microM), phosphatidylinositol 3-kinase (PI3K), wortmannin (0.01 microM), PKC (protein kinase C), GF109203 (10 microM), calcium/calmodulin kinase II (CaMKII), and KN-93 (20 microM) partially attenuated the stimulatory effect of olanzapine on BDNF promoter activity. In line with these results, a Western blot study showed that olanzapine (100 microM) increased phosphorylated levels of GSK-3beta and CREB, which are notable downstream effectors of the PKA, PI3K, PKC, and CaMKII signaling pathways. CONCLUSIONS: These results demonstrate that the up-regulation of olanzapine on BDNF gene transcription is linked with enhancement of CREB-mediated transcription via PKA, PI3K, PKC, and CaMKII signaling pathways, and olanzapine may exert neuroprotective effects through these signaling pathways in neuronal cells.
机译:目的:非典型抗精神病药具有神经保护作用,这可能是其成功治疗精神分裂症的机制之一。越来越多的证据表明,精神分裂症患者的脑源性神经营养因子(BDNF)异常调节,并且非典型抗精神病药可以上调其表达。非典型抗精神病药可能会积极调节BDNF基因的转录,但尚未研究非典型抗精神病药对BDNF基因活性的分子机制。本研究的目的是探讨奥氮平对BDNF启动子活性的某些细胞内信号通路可能的参与。方法:我们研究了奥氮平对用荧光素酶报道基因连接的大鼠BDNF启动子片段(-108至+340)转染的SH-SY5Y细胞中BDNF基因启动子活性的影响。通过蛋白质印迹分析测量糖原合酶激酶3beta(GSK-3beta)和cAMP反应元件(CRE)结合蛋白(CREB)磷酸化的变化。结果:奥氮平治疗(10-100 microM)以剂量依赖性方式增加了基础BDNF基因启动子活性,并在高剂量下增加了蛋白质水平,并且蛋白激酶A(PKA),H-89(10 microM)和磷脂酰肌醇3抑制剂激酶(PI3K),渥曼青霉素(0.01 microM),PKC(蛋白激酶C),GF109203(10 microM),钙/钙调蛋白激酶II(CaMKII)和KN-93(20 microM)部分减弱了奥氮平对下列药物的刺激作用BDNF启动子活性。与这些结果一致,蛋白质印迹研究表明,奥氮平(100 microM)增加了GSK-3beta和CREB的磷酸化水平,这是PKA,PI3K,PKC和CaMKII信号通路的重要下游效应物。结论:这些结果表明奥氮平对BDNF基因转录的上调与CREB介导的通过PKA,PI3K,PKC和CaMKII信号通路的转录增强有关,奥氮平可能通过这些信号通路在神经元细胞中发挥神经保护作用。 。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号